A promoter variant of the APOA5 gene increases atherogenic LDL levels and arterial stiffness in hypertriglyceridemic patients

Minjoo Kim, Minkyung Kim, Hye Jin Yoo, Eunji Lee, Jey Sook Chae, Sang Hyun Lee, Jong Ho Lee

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


Hypertriglyceridemia is recognized as an independent risk factor for coronary artery disease. The apolipoprotein A5 gene (APOA5) is a key regulator of triglyceride levels. We aimed to evaluate the associations of single nucleotide polymorphisms (SNPs) in APOA5, including -1131T>C and c.553G>T, with hypertriglyceridemia, apoA5 concentrations, atherogenic LDL cholesterol levels, and arterial stiffness in hypertriglyceridemic patients. The study population included 599 hypertriglyceridemic patients (case) and 1,549 untreated normotriglyceridemic subjects (control). We genotyped two APOA5 variants, -1131T>C (rs662799) and c.553G>T (rs2075291). The frequencies of the CC genotype of -1131T>C (0.165) and the T allele of c.553G>T (0.119) were significantly higher in hypertriglyceridemic patients than in normotriglyceridemic subjects (0.061 and 0.070, respectively; all p<0.001). In the control and case groups, both the -1131T>C and c.553G>T variants were associated with higher triglyceride and lower HDL cholesterol levels. Controls with the -1131CC variant had lower apoA5 concentrations than controls with the -1131TT variant. Similar effects of the -1131T>C variant on apoA5 were observed in the cases. In the hypertriglyceridemic group, the -1131T>C variant was associated with a smaller LDL particle size, higher levels of oxidized LDL and malondialdehyde, and higher brachial-ankle pulse wave velocity. The -1131T>C and c.553G>T polymorphisms were associated with hypertriglyceridemia in the study population, but only the -1131T>C polymorphism directly affected apoA5 concentrations. Hypertriglyceridemic patients carrying the APOA5 -1131T>C polymorphism exhibited increased atherogenic LDL levels and arterial stiffness, probably due to an effect of the -1131T>C polymorphism on apoA5 concentrations.

Original languageEnglish
Article numbere0186693
JournalPloS one
Issue number12
Publication statusPublished - 2017 Dec

Bibliographical note

Funding Information:
This study was funded by the Bio-Synergy Research Project (NRF-2012M3A9C4048762) and the Mid-career Researcher Program (NRF-2016R1A2B4011662) of the Ministry of Science and by ICT and Future Planning through the National Research Foundation of the Republic of Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The genotype data were generated using Korean Chip (K-CHIP), which is available through the K-CHIP consortium. K-CHIP was designed by the Center for Genome Science at the Korea National Institute of Health, Korea (4845–301, 3000–3031).

Publisher Copyright:
© 2017 Kim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

All Science Journal Classification (ASJC) codes

  • General


Dive into the research topics of 'A promoter variant of the APOA5 gene increases atherogenic LDL levels and arterial stiffness in hypertriglyceridemic patients'. Together they form a unique fingerprint.

Cite this